Truist raised the firm’s price target on Tenet Healthcare (THC) to $190 from $175 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Billions of dollars of Medicaid payments for hospitals delayed, WSJ reports
- Tenet Healthcare: Strong Performance and Growth Potential Justify Buy Rating Despite Lowered Price Target
- Tenet Healthcare price target raised to $189 from $183 at RBC Capital
- Tenet Healthcare price target raised to $230 from $217 at UBS
- Tenet Healthcare price target raised to $180 from $165 at Guggenheim